4 May 2023
Worsening Heart Failure (WHF) is a major public health concern, responsible for >26 million hospitalizations per year worldwide. Many trials have investigated new therapeutic options for WHF, with most revealing equivocal results. Successful innovations in treatment for WHF have remained limited, and standard of care has remained largely unchanged over the past decade.
Current treatment of WHF is mostly symptomatic, centred on decongestive drugs, at best tailored to the initial haemodynamic status with little regard to the underlying pathophysiological mechanism. Although short-term readmissions are due to haemodynamic congestion, long-term prognosis and mortality are the result of the continuous deterioration of cardiac substrate, worsening of comorbidities, and progression of heart failure. Vericiguat, a soluble guanylate cyclase stimulator, targets an untapped pathway in this new high risk patient population of WHF to improve the cardiovascular outcomes.
After the lecture, the participants will be able to gain an understanding on:
Click here for more lecture details.
To register (internet access is required), scan the QR code or click on the web link. Registration closes on 17 April 2023, Monday.
https://form.gov.sg/640a93c79a4133001225b3f1
Upon registration, participants agreed to PGAHI Terms & Conditions. Kindly note that PGAHI reserves the right of final decision on lecture registration.
Lecture Details
Date:
4 May 2023, Thursday
Timing:
6.30 pm - 7.30 pm
Duration:
60 minutes
Fees:
Complimentary
Platform:
Zoom Cloud Meetings
Registration Closing Date:
17 April 2023, Monday
Target Audience:
Pharmacists
(Zoom Capacity: 500
This lecture will be conducted via Zoom Cloud Meetings app. For ease of accessing the lecture, please download/update Zoom Cloud Meetings app. Details of the lecture meeting link will be sent to the successful registrants nearer the lecture date.)
